Does Blue Cross Blue Shield of Minnesota Cover Forteo?

What Is Forteo and Why Does It Require Special Coverage Rules?

Forteo is the brand name for teriparatide, a recombinant fragment of human parathyroid hormone (PTH 1-34). Unlike bisphosphonates such as alendronate or risedronate, which slow bone resorption, teriparatide actively stimulates new bone formation. That anabolic mechanism makes it genuinely effective for severe osteoporosis, but it also makes it expensive and tightly regulated by both the FDA and payers.

The FDA's 24-Month Lifetime Limit

The FDA label restricts cumulative lifetime use to 24 months across all PTH analogs, including both Forteo and its competitor abaloparatide (Tymlos). Blue Cross Blue Shield plans universally encode this restriction into their coverage criteria. Insurers track the lifetime clock regardless of which plan the patient held when therapy started, so prior teriparatide use from years ago still counts.

Why Insurers Treat Forteo as a Specialty Drug

At a wholesale acquisition cost of roughly $3,100 per month, teriparatide sits comfortably in the specialty tier of nearly every commercial formulary. The FDA approved teriparatide in 2002 and an authorized generic became available in 2019, giving plans additional flexibility to prefer lower-cost alternatives. BCBS Minnesota, like most large regional Blues plans, uses formulary placement and prior authorization to steer patients through less expensive agents before approving anabolic therapy.

How BCBS Minnesota Formularies Work for Osteoporosis Drugs

BCBS Minnesota offers multiple product lines: commercial fully-insured, self-funded employer (ASO), Medicare Advantage (Blue Cross Advantage), and Medicaid managed care (through its subsidiary). Each product line may have a different formulary, so there is no single answer that covers every BCBS MN member.

Commercial Formularies

On most standard commercial plans, osteoporosis drugs are organized roughly as follows:

• Tier 1 to 2: Generic alendronate, risedronate, ibandronate
• Tier 3: Brand bisphosphonates (Fosamax, Actonel), raloxifene (Evista)
• Tier 4 Specialty: Forteo (teriparatide), Tymlos (abaloparatide), Prolia (denosumab), Evenity (romosozumab)

Teriparatide generics may land on Tier 3 or Tier 4 depending on the contract year and employer negotiation. Always verify the exact tier by entering the drug on the BCBS Minnesota online formulary tool or calling the member services number on the back of your insurance card.

Medicare Advantage Plans

Under Medicare Part D formulary rules, plans must cover at least two drugs in each therapeutic class. BCBS MN's Medicare Advantage plans typically place Forteo or its generic on a non-preferred specialty tier with a coinsurance of 25 to 33% in the coverage gap phase. The 2024 Inflation Reduction Act changes cap Medicare Part D out-of-pocket spending at $3,300 for the year (and $2,000 from 2025 forward), which meaningfully lowers the worst-case annual cost for Medicare beneficiaries. The CMS guidance on Part D cost-sharing reforms is available here.

Self-Funded Employer Plans

Self-funded plans administered by BCBS MN set their own formularies and prior authorization criteria. The employer, not BCBS, is the ultimate decision-maker. This matters because some self-funded employers exclude anabolic osteoporosis drugs entirely, while others offer richer coverage than standard commercial plans. Ask your HR department for the Summary of Benefits and Coverage (SBC) and the full formulary document.

Prior Authorization Criteria for Forteo Under BCBS Minnesota

Prior authorization (PA) is essentially universal for Forteo under BCBS MN plans. The prescribing clinician submits a PA request; the plan's pharmacy or medical management team reviews it against published criteria.

Typical Approval Criteria

While specific criteria shift with each contract year, the following requirements appear consistently across BCBS MN commercial products:

1. Diagnosis of osteoporosis confirmed by DXA T-score of -2.5 or below at the lumbar spine, total hip, or femoral neck, OR a documented low-trauma (fragility) fracture. The National Osteoporosis Foundation clinical guidelines define fragility fracture as a fracture occurring from a fall from standing height or less.
2. Step therapy completion. The patient must have tried and had an inadequate response to, or a documented intolerance of, at least one oral bisphosphonate (typically alendronate 70 mg weekly for at least 12 months or its equivalent). Documented side effects such as esophageal irritation, atypical femur fracture risk, or osteonecrosis of the jaw may substitute for a true treatment trial.
3. High fracture risk. Many plans additionally require a FRAX 10-year major osteoporotic fracture probability at or above 20%, or a hip fracture probability at or above 3%, thresholds endorsed by the American Association of Clinical Endocrinology. The AACE/ACE 2020 clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis describe these risk categories in detail.
4. No prior anabolic lifetime exhaustion. The plan verifies that the patient has not already received 24 months of teriparatide or abaloparatide.
5. Prescriber specialty. Some plans require the prescribing physician to be a rheumatologist, endocrinologist, or other relevant specialist, particularly for first-time anabolic prescriptions.

Duration of Initial Approval

Initial authorizations are typically granted for 6 months. The prescriber then submits a renewal PA demonstrating ongoing clinical benefit, usually defined as stable or improving BMD on serial DXA and adherence to calcium (1,000 to 1,200 mg/day) and vitamin D (800 to 1,000 IU/day) supplementation.

Step Therapy: The Bisphosphonate Requirement in Detail

Step therapy requirements are the single most common reason a Forteo PA is delayed or initially denied. Understanding exactly what counts as a "step" saves weeks of back-and-forth between the prescriber's office and the insurer.

What Qualifies as an Adequate Bisphosphonate Trial

An adequate trial is generally defined as:

• Alendronate 70 mg once weekly for at least 12 consecutive months, OR
• Risedronate 35 mg once weekly or 150 mg once monthly for 12 months, OR
• Ibandronate 150 mg once monthly for 12 months, OR
• Zoledronic acid 5 mg IV annually for at least one infusion (often accepted as equivalent to 12 months of oral therapy given its pharmacokinetic profile).

A trial is typically deemed inadequate if the patient experienced a new fragility fracture on therapy, if BMD declined by more than 4 to 5% at the spine or hip on serial DXA, or if the patient had documented GI intolerance requiring discontinuation.

Exceptions to Step Therapy

Several clinical scenarios allow a prescriber to bypass step therapy entirely:

• Documented esophageal stricture or achalasia precluding oral bisphosphonate use
• Prior history of atypical femoral fracture attributed to bisphosphonate use (supported by the 2016 ASBMR task force report)
• Glucocorticoid-induced osteoporosis with T-score below -2.5 and current prednisone dose at or above 7.5 mg/day for 3 or more months (a scenario where anabolic therapy is specifically endorsed by the American College of Rheumatology)
• Multiple vertebral fractures on a baseline imaging study, indicating immediately high fracture risk

The prescriber's PA letter should explicitly invoke one of these exceptions and attach supporting documentation.

What Happens After a Denial: The Appeals Process

A first-level PA denial is not the end of the road. BCBS Minnesota, like all ACA-compliant insurers, must provide an internal appeal process and, if the internal appeal fails, an external independent review.

Level 1: Internal Appeal

The prescriber or patient submits a formal appeal within the window specified in the denial letter (often 180 days for commercial plans). The appeal should include:

• A detailed clinical letter from the treating physician explaining medical necessity
• DXA results with T-scores and Z-scores
• A fracture history with imaging reports if available
• Documentation of bisphosphonate side effects or treatment failure
• Reference to specific guideline language (e.g., AACE 2020, Endocrine Society guidelines)

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states directly that teriparatide is appropriate for women at very high fracture risk, defined as T-score below -3.0 or a prior vertebral fracture. Quoting this guideline language in the appeal letter gives the reviewing physician a named, peer-reviewed standard to reference.

Level 2: External Independent Review

If the internal appeal is denied, the patient may request an external review by an independent review organization (IRO). Minnesota state law requires BCBS MN to comply with the IRO decision. External reviews for specialty drugs that carry strong guideline support tend to have meaningful overturn rates, though published data specific to teriparatide external reviews are limited.

Expedited Appeal

If a delay in starting Forteo poses a serious health risk (for example, a patient with two recent vertebral fractures who is at imminent risk of another), an expedited appeal can be requested. BCBS MN must respond to an expedited appeal within 72 hours.

Cost and Savings Programs If Coverage Is Denied or Cost-Sharing Is High

Even with insurance coverage, specialty tier cost-sharing can make Forteo unaffordable. Several programs reduce out-of-pocket costs substantially.

Lilly Cares Foundation

The Lilly Cares Foundation Patient Assistance Program provides free Forteo to uninsured or underinsured patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level). Applications are available through the NeedyMeds database or directly through Lilly.

Forteo Savings Card (Commercial Insurance Only)

Eli Lilly's co-pay savings card may reduce monthly out-of-pocket costs to as low as $25 for commercially insured patients. Patients on Medicare, Medicaid, or other government programs are not eligible. The savings card does not apply to deductible or out-of-pocket maximum accumulation under some high-deductible plans, so confirm the mechanics with the specialty pharmacy.

Teriparatide Generic Cost Advantage

The FDA-approved teriparatide injection (authorized generic) carries a list price roughly 40 to 60% below brand Forteo. If BCBS MN places the generic on a lower formulary tier, using it can cut cost-sharing significantly while delivering identical pharmacology. Ask the prescriber specifically to write "teriparatide injection" rather than "Forteo" if the generic enjoys better coverage.

State Pharmaceutical Assistance Programs

Minnesota does not currently operate a broad state pharmaceutical assistance program comparable to those in New Jersey or Pennsylvania, but the Minnesota Department of Human Services administers programs for qualifying low-income individuals that may cover specialty osteoporosis drugs.

Clinical Evidence Supporting Forteo Coverage: Why the PA Is Worth Pursuing

Understanding the clinical data behind teriparatide helps patients and providers make the case for coverage and understand what they are trying to achieve.

The Fracture Prevention Trial (FPT)

The landmark randomized controlled trial by Neer et al. (N=1,637), published in the New England Journal of Medicine in 2001, showed that teriparatide 20 mcg/day reduced new vertebral fractures by 65% (relative risk 0.35, 95% CI 0.22 to 0.55, P<0.001) and nonvertebral fragility fractures by 53% (RR 0.47, 95% CI 0.25 to 0.88) compared with placebo over a median 21-month follow-up. The full trial report is available on PubMed.

VERO Trial: Teriparatide vs. Risedronate

The VERO trial (N=1,360) compared teriparatide directly against risedronate 35 mg weekly in postmenopausal women with severe osteoporosis. At 24 months, teriparatide reduced new clinical vertebral fractures by 56% relative to risedronate (RR 0.44, P<0.0001) and reduced nonvertebral fractures by 52% (P=0.040). The VERO data are published in The Lancet. This head-to-head evidence is particularly useful in PA appeals because it demonstrates superiority over the bisphosphonate step-therapy requirement, not just superiority over placebo.

Lumbar Spine BMD Gains

A meta-analysis of 26 randomized controlled trials published in JAMA Internal Medicine found that teriparatide produced a mean lumbar spine BMD gain of approximately 9.8% at 18 to 24 months, the largest gain of any approved osteoporosis agent. The JAMA Network publication is here. Documenting a patient's baseline DXA and projecting expected BMD response can strengthen the medical necessity argument.

The Prescriber's Role in Securing BCBS MN Coverage

Physicians and advanced practice providers play the largest single role in whether a Forteo PA is approved on the first submission. Incomplete or generic PA letters are the leading cause of first-time denials.

Writing an Effective PA Letter

A PA letter that consistently secures approval for Forteo under BCBS MN plans should include the following structured elements:

1. Patient demographics and diagnosis: Age, sex, menopause status or testosterone level if relevant, diagnosis code (M81.0 for postmenopausal osteoporosis without current pathological fracture, M80.08 for vertebral fracture, etc.).
2. DXA results with dates: Include the T-score at each measured site and the name of the facility that performed the scan.
3. Fracture history: List each fracture with date, anatomic site, mechanism, and imaging confirmation. Specify whether it qualifies as a fragility fracture.
4. Prior therapy documentation: Name each bisphosphonate tried, dose, duration, and reason for discontinuation or failure. Attach pharmacy records if available.
5. FRAX score: Include the 10-year probability for major osteoporotic fracture and hip fracture, with the input variables listed.
6. Guideline citation: Quote the specific AACE 2020 or Endocrine Society 2019 recommendation that supports anabolic therapy in this patient's risk category.
7. Proposed regimen: State "teriparatide 20 mcg subcutaneous injection once daily for 24 months" and specify the transition plan to antiresorptive therapy (typically denosumab or zoledronic acid) upon completion, which is required to preserve BMD gains.

A letter structured this way gives the PA reviewer everything needed to approve on first submission and leaves no clinical gaps for the denial team to exploit.

Monitoring Parameters During Coverage Period

BCBS MN renewal PAs typically require evidence of ongoing monitoring. Clinicians should plan for:

• Repeat DXA at 12 months and at 24 months (end of therapy)
• Serum calcium at baseline and at 1 month (teriparatide transiently raises serum calcium in some patients)
• 24-hour urine calcium if hypercalciuria is suspected
• Assessment for and documentation of adverse effects at each visit

Transitioning Off Forteo: Coverage for Sequential Therapy

The clinical benefit of teriparatide is substantially lost if antiresorptive therapy does not follow immediately. Several trials, including the DATA-Switch trial published in The Lancet, show that BMD gains can be largely preserved with sequential denosumab. The DATA-Switch trial abstract is accessible on PubMed.

BCBS MN coverage for the sequential antiresorptive agent is a separate PA process. Prescribers should begin that PA approximately 60 days before the patient's 24th teriparatide dose to avoid any gap in therapy. Denosumab (Prolia 60 mg subcutaneous every 6 months) also requires PA under most BCBS MN plans, but the criteria are less restrictive than for anabolic agents.